Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Diabetes Mellitus - Type 1
- Postprandial Hyperglycemia
- Type 1 Diabetes
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: This is a two-way, randomized, open-label, controlled, crossover trial to compare the following strategies: (i) Rapid insulin-plus-Pramlintide closed-loop delivery (ii) Rapid insulin-plus-Placebo closed-loop deliveryMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04243629
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Investigators
- Not Provided